Samsung Biologics
207940.KS · Bio
World's largest contract biologics manufacturer (CDMO). Produces biosimilars and biologics for global pharma.
Latest news
Samsung Electro-Mechanics Tops Shareholder Returns at 755%; LG Energy, Samsung Biologics Post Losses
Samsung Biologics Jumps 5% Premarket as Moderna Soars 177%
Gyeonggi Opens Applications for G-BIO Week 2026 Partnering
Samsung Awards Scholarships to 15 Korean Science Olympiad Medalists
Samsung Biologics Union Backs Down on Bonus Demands, Agrees to Mediation
Samsung Biologics Wins End-to-End Big Pharma Deals
Korea Corporate Bond Sales Hit 4-Year Low as Big Firms Delay Issuance
K-Bio Emerges as Korea's Next Growth Engine After Chips
SK Pharmteco Completes Obesity-Drug API Plant, Sets Up Peptide CDMO Clash With Samsung
Samsung Biologics Surges 11% as KOSPI Plunges on Strong Earnings
Samsung Biologics to Sustain Growth on Rockville, Plant 5
Samsung Biologics Tops 1 Trillion Won H1 Operating Profit, Nears 5 Trillion Club
Corporate Disclosures
Samsung Biologics Posts Record 1.32 Trillion Won Q2 Revenue on Higher Utilization
Samsung Biologics Q2 Operating Profit Rises 22.9% to 586.4 Billion Won
Samsung Biologics Acquires PolyPeptide for 2.7 Trillion Won, Expanding Growth Axis Beyond Antibodies
Samsung Biologics Seals 2.7 Trillion Won Deal for Wegovy Ingredient Maker
Why Samsung's 2.7 Trillion Won Deal Signals Its Galaxy Healthcare Push
Today's Disclosures
Samsung Biologics Shares Slip Early After 2.7 Trillion Won Acquisition
Samsung Biologics to Acquire Peptide CDMO for 2.7 Trillion Won
Keytruda Patent Expires in Two Years; Samsung Bioepis Targets 47 Trillion Won Market with In-House Technology
